Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

Background It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment. Objectives To evaluate supplementing dichotomous efficacy with residual disease activity. Methods This post hoc analysis used pooled, patient-level data after t...

Full description

Bibliographic Details
Main Authors: K. B. Gordon, K. Reich, J. J. Crowley, N. J. Korman, F. T. Murphy, Y. Poulin, L. Spelman, P. S. Yamauchi, A. M. Mendelsohn, J. Parno, S. J. Rozzo, C. N. Ellis
Format: Article
Language:English
Published: Taylor & Francis Group 2022-01-01
Series:Journal of Dermatological Treatment
Subjects:
psoriasis
disease activity
tildrakizumab
psoriasis area and severity index (pasi)
Online Access:http://dx.doi.org/10.1080/09546634.2020.1747590

Internet

http://dx.doi.org/10.1080/09546634.2020.1747590

Similar Items